Literature DB >> 3951357

Parenteral gold therapy in the Felty syndrome. Experience with 20 patients.

A M Dillon, H S Luthra, D L Conn, R H Ferguson.   

Abstract

Most of the patients with the Felty syndrome suffer from such complications as fevers, infections, cutaneous ulcers, and vasculitis. Unfortunately, there are no therapeutic interventions that are predictably beneficial. We report our experience with 20 patients who received parenteral gold therapy for 2 to 114 months (mean, 23.6 months). All had complications of the Felty syndrome. On parenteral gold therapy, 60% had a complete response, 20% had a partial response, and 20% were unresponsive by preselected criteria. No serious complications were encountered. We think that parenteral gold therapy should be considered early, before other agents, in the treatment of this condition.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3951357     DOI: 10.1097/00005792-198603000-00003

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  2 in total

1.  Liver disease in twins with Felty's syndrome.

Authors:  R J Moots; E Elias; S Hubscher; M Salmon; P Emery
Journal:  Ann Rheum Dis       Date:  1994-03       Impact factor: 19.103

Review 2.  Primary and secondary autoimmune neutropenia.

Authors:  Franco Capsoni; Piercarlo Sarzi-Puttini; Alberto Zanella
Journal:  Arthritis Res Ther       Date:  2005-08-31       Impact factor: 5.156

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.